Habituation of the Nociceptive Blink Reflex in Experimentally Induced Migraine Attack
NCT05718310 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22
Last updated 2023-02-08
Summary
People with migraine typically show impaired responsivity to visual, auditory and pain stimuli (Burstein et al, 2015). The electrophysiological study of the nociceptive blink reflex (nBR) is widely adopted for the instrumental evaluation of trigeminal afferent function.
Migraine sufferers characteristically show deficits in the habituation to repeated stimulations of various sensory modalities, in the interictal phase of the disease (Bohotin et al, 2002; Di Clemente et al, 2005).
It has been described how the habituation / sensitization pattern presents a characteristic pattern over the course of the migraine cycle. Past evidence suggests that the habituation deficit may turn towards a normalization of the pattern near the acute migraine attack (Coppola et al, 2013; Katsarava et al, 2003).
However, the study of the spontaneous attack shows various limits and difficulties, mainly due to the impossibility of predicting the onset of the next attack and of standardizing the experimental conditions. The use of human models of migraine allows us to overcome these obstacles. Di Clemente et al. (2009) evaluated the electrophysiological changes in nBR after administration of nitroglycerin (NTG) in healthy subjects. The authors described a modification of trigeminal circuits and cortical responses (visual evoked potentials) after NTG. However, NTG administration does not induce migraine attack in healthy subjects, therefore this model cannot be directly translated to migraine pathology (Ashina et al. 2017).
Our group has previously used the human model of migraine based on the administration of NTG to study central and spinal level sensitization through the nociceptive avoidance reflex in the lower limb (RIII) (De Icco et al. 2020). The results of the previous study deepened our understanding of the central mechanisms of sensitization.
The investigation of the nBR allows to study the modulation of the caudal trigeminal complex (TCC). In the present study we therefore intend to evaluate, under well-controlled experimental conditions, the modulation of the trigeminal caudal complex during an experimentally induced migraine attack. The study will allow us to confirm or not the normalization of habituation described in the acute phase through the adoption of a solid cross-over and placebo-controlled study design.
Conditions
Interventions
- DRUG
-
Nitroglycerin
25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
- DRUG
-
Saline
25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
Sponsors & Collaborators
-
University of Pavia
collaborator OTHER -
IRCCS National Neurological Institute "C. Mondino" Foundation
lead OTHER
Principal Investigators
-
Roberto De Icco, MD · IRCCS, Mondino Foundation
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- TRIPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-01
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
Countries
- Italy
Study Locations
More Related Trials
-
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
NCT01899040 ·Status: COMPLETED ·Phase: NA
-
Defining the Sympathetic Skin Response of Migraineurs in the Facial Area
NCT03772860 ·Status: UNKNOWN
-
Psychological and Biological Markers of Refractory Migraine
NCT05046119 ·Status: UNKNOWN
-
Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine
NCT04361721 ·Status: UNKNOWN
-
Study of the Glymphatic System in Migraine
NCT05907655 ·Status: RECRUITING
-
Treatment of Episodic Migraine With AURICular Neuromodulation
NCT06623188 ·Status: RECRUITING ·Phase: NA
-
Mind and Body Approaches to Pain Reduction in Youth With Migraine
NCT03472092 ·Status: COMPLETED ·Phase: PHASE2
-
The Identification and Characterization of Autonomic Dysfunction in Migraineurs With and Without Auras
NCT01080287 ·Status: COMPLETED
-
Study With Amitriptylin to Evaluate the Efficacy of Melatonin in Treatment of Migraine
NCT01357031 ·Status: COMPLETED ·Phase: PHASE3
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
NCT07061847 ·Status: RECRUITING ·Phase: PHASE2
-
Stimulation-evoked Calcitonin Gene-Related Peptide (CGRP) as Biomarker of Migraine
NCT05768828 ·Status: UNKNOWN
-
Vagus Nerve Stimulation and Stress Reduction Training for Migraine
NCT03592329 ·Status: COMPLETED ·Phase: NA
-
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
NCT03488563 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Tinnitus With Migraine Medications
NCT04404439 ·Status: COMPLETED ·Phase: PHASE4
-
Prediction of Migraine Prevention Efficacy Based on Individual's Pain Modulation
NCT02101892 ·Status: COMPLETED ·Phase: NA
-
Treximet in Acute Migraine Headache: Assessing Cognitive Function
NCT00837044 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Nerivio Device for Acute Treatment of Migraine in People With Chronic Migraine
NCT04194008 ·Status: COMPLETED ·Phase: NA
-
The Evaluation of the Transcutaneous Electrical Stimulation Medical Device's Safety and Effectiveness in Treating the Patients With Migraine
NCT05301920 ·Status: COMPLETED ·Phase: NA
-
Post-marketing Clinical Trial of Elexir(Trigeminal Nerve Electrical Stimulator) for the Acute Treatment of Migraine
NCT06170411 ·Status: RECRUITING ·Phase: NA
-
Transcranial Direct Current Stimulation Plus Monoclonal Antibodies Acting on the CGRP Pathway for Migraine
NCT05161871 ·Status: COMPLETED ·Phase: NA
-
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
NCT03977649 ·Status: COMPLETED ·Phase: PHASE4
-
Topiramate and Cerebrovascular Response in Migraineurs
NCT02424318 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
NCT01617941 ·Status: WITHDRAWN ·Phase: PHASE2
-
Decoding Pain Sensitivity in Migraine With Multimodal Brainstem-based Neurosignature
NCT04702971 ·Status: RECRUITING ·Phase: PHASE4
-
Neurostimulation Device for Treatment of Migraine Headache
NCT01630044 ·Status: COMPLETED ·Phase: NA